LPTX

-- -- --

From December 31, 2022 to December 31, 2023 Conversion of Series X preferred stock to common stock Fractional shares paid in cash Issuance of Series X Preferred Stock in connection with Flame merger Issuance of common stock upon vest of restricted stock units

Leap Therapeutics, Inc. announced that it will effect a 10-for-1 reverse stock split of its issued and outstanding common stock, effective at 5PM ET on June 20, 2023.

From December 31, 2022 to March 31, 2023 Issuance of Series X Preferred Stock in connection with Flame merger Issuance of common stock in connection with Flame merger Issuance of common stock upon vest of restricted stock units

From June 30, 2021 to September 30, 2021 Issuance of common stock upon exercise of warrants Issuance of common stock upon exercise of prefunded warrants Issuance of common stock and prefunded warrants in connection with September 2021 Public Offering, net of issuance costs of $6,733

1.Shares the company are offering 22,828,072 shares of common stock. 2.The number of shares of common stock to be outstanding immediately after this offering as shown above, is based on 59,709,041 shares of common stock outstanding as September 17, 2021.

From March 31, 2021 to May 10, 2021 Issuance of common stock upon exercise of stock options

From December 31, 2020 To March 31, 2021 Issuance of common stock upon exercise of warrants

From March 31, 2020 to June 30, 2020 Issuance of common stock in connection with June 2020 Public Offering, net of issuance costs of $3,472 Issuance of common stock upon exercise of stock options Issuance of common stock upon exercise of warrants

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an additional 3,375,000 shares of common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares from Leap’s previously announced public offering.

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 20,250,000 shares of common stock and pre-funded warrants to purchase up to 2,250,000 shares of its common stock.

From December 31, 2019 to March 11, 2020 Issuance of Series A & B Convertible Preferred Stock, net of underwriting discounts Conversion of Series A Convertible Preferred Stock to prefunded warrants Conversion of Series B Convertible Preferred Stock to common stock Issuance of common stock upon exercise of stock options Issuance of common stock upon exercise of warrants

From June 30, 2019 to September 30, 2019 Issuance of common stock through ATM sales Issuance of common stock in connection with July 2019 Lincoln Park Capital Commitment Purchase Agreement Issuance of common stock in connection with July 2019 Lincoln Park Capital Registered Offering Purchase Agreement, net of issuance costs of $10

From March 31, 2019 to April 26, 2019 Issuance of common stock through ATM sales

From December 31, 2018 to March 26, 2019 Issuance of common stock in connection with February 2019 Public Offering, net of issuance costs of $1,102 On February 5, 2019, the Company completed a public offering whereby the Company issued 7,557,142 shares of its common stock at a price of $1.75 per share, which included 985,714 shares issued pursuant to the underwriters' exercise of their option to purchase additional shares of common stock, each share issued with a warrant to purchase one share of common stock. Each warrant has an exercise price of $1.95 per share with an exercise period expiring seven years from the date of issuance.

From December 31, 2017 to September 30, 2018 Issuance of common stock in connection with Public Offering, net of issuance costs of $1,304 Issuance of common stock upon exercise of warrants Issuance of common stock upon exercise of stock options

From December 31, 2017 to May 8, 2018 Issuance of common stock in connection with Public Offering, net of issuance costs of $1,304 Issuance of common stock upon exercise of warrants

from December 31, 2017 to March 31, 2018 Issuance of common stock in connection with Public Offering, net of issuance costs of $1,304

from December 31, 2016 to December 31, 2017 Conversion of notes payable—related party and accrued interest into common stock Conversion of convertible preferred stock to common stock Issuance of common stock in connection with the Subscription Agreement, net of issuance costs of $1,018 Issuance of common stock in connection with merger with Macrocure, net of offering costs of $1,331 Issuance of common stock upon exercise of stock options Issuance of common stock in connection with the Private Placement, net of issuance costs of $236

from December 31, 2016 to June 30, 2017 Conversion of notes payable - related party and accrued interest into common stock Conversion of convertible preferred stock to common stock Accretion to redemption value Issuance of common stock, net of issuance costs of $947 Issuance of common stock in connection with merger with Macrocure, net of offering costs of $1,402 Issuance of common stock upon exercise of stock options

from December 31, 2016 to March 31, 2017 Accretion to redemption value Conversion of convertible preferred stock to common stock Conversion of notes payable - related party and accrued interest into common stock Issuance of common stock, net of issuance costs of $947 Issuance of common stock in connection with merger with Macrocure, net of offering costs of $1,402